Cargando…

Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients

BACKGROUND: Fibroblast growth factor 19 (FGF19) takes part in maintaining the balance of glycolipids and may be involved in regulating the secretory activity of islet beta cells in patients with type 2 diabetes. This study aimed to evaluate the relationship between the levels of serum FGF19 and endo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Meng-jie, Su, Jian‑bin, Xu, Tian-li, Wang, Xue‑qin, Zhang, Dong-mei, Wang, Xiao-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760053/
https://www.ncbi.nlm.nih.gov/pubmed/31572498
http://dx.doi.org/10.1186/s13098-019-0475-1
_version_ 1783453805120061440
author Tang, Meng-jie
Su, Jian‑bin
Xu, Tian-li
Wang, Xue‑qin
Zhang, Dong-mei
Wang, Xiao-hua
author_facet Tang, Meng-jie
Su, Jian‑bin
Xu, Tian-li
Wang, Xue‑qin
Zhang, Dong-mei
Wang, Xiao-hua
author_sort Tang, Meng-jie
collection PubMed
description BACKGROUND: Fibroblast growth factor 19 (FGF19) takes part in maintaining the balance of glycolipids and may be involved in regulating the secretory activity of islet beta cells in patients with type 2 diabetes. This study aimed to evaluate the relationship between the levels of serum FGF19 and endogenous islet beta cell function in type 2 diabetic patients. METHODS: Samples were obtained from 271 subjects: 85 drug-naïve type 2 diabetes participants exclusively on lifestyle intervention (N-DM group), 122 type 2 diabetes subjects previously used medications (DM group) and 64 normal controls (NC group). Serum FGF19 concentrations were measured by ELISA. The insulin sensitivity (MI), insulin secretion (AUC(ins)/AUC(glu)) and insulin secretion-sensitivity index-2 (ISSI-2) were also measured in the N-DM and DM. RESULTS: Serum FGF19 levels decreased, in order, from the NC group [median (interquartile range), 245.03 (126.23–317.43) pg/mL] to the N-DM group [170.05 (89.01–244.70) pg/mL] and, finally, to the DM group [142.25 (55.55–187.58) pg/mL] (p for trend < 0.05). Among subjects in the DM group, there was a positive trend in the serum FGF19 concentration; plasma insulin levels at 60 min, 120 min (INS60, INS120, respectively); and area under the insulin curve (AUC(ins)) at two points (r = 0.214, p = 0.025; r = 0.189, p = 0.048; r = 0.188, p = 0.049). However, the differences were no longer observed among the N-DM subjects. Simultaneously, the ISSI-2 was closely related to the serum FGF19 levels (r = 0.297, p = 0.002) among DM subjects. Furthermore, after adjusting for age, sex, duration, therapy and other clinical factors via multiple logistic regression analysis, ISSI-2 was a key independent factor in the levels of FGF19 (β = 0.281, t = 2.557, p = 0.013). CONCLUSIONS: The serum FGF19 level has a close relation with endogenous beta cell function among DM subjects, as assessed by the ISSI-2. As ISSI-2 is higher in N-DM group, FGF19 may be a main protector in dysfunction of beta cell.
format Online
Article
Text
id pubmed-6760053
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67600532019-09-30 Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients Tang, Meng-jie Su, Jian‑bin Xu, Tian-li Wang, Xue‑qin Zhang, Dong-mei Wang, Xiao-hua Diabetol Metab Syndr Research BACKGROUND: Fibroblast growth factor 19 (FGF19) takes part in maintaining the balance of glycolipids and may be involved in regulating the secretory activity of islet beta cells in patients with type 2 diabetes. This study aimed to evaluate the relationship between the levels of serum FGF19 and endogenous islet beta cell function in type 2 diabetic patients. METHODS: Samples were obtained from 271 subjects: 85 drug-naïve type 2 diabetes participants exclusively on lifestyle intervention (N-DM group), 122 type 2 diabetes subjects previously used medications (DM group) and 64 normal controls (NC group). Serum FGF19 concentrations were measured by ELISA. The insulin sensitivity (MI), insulin secretion (AUC(ins)/AUC(glu)) and insulin secretion-sensitivity index-2 (ISSI-2) were also measured in the N-DM and DM. RESULTS: Serum FGF19 levels decreased, in order, from the NC group [median (interquartile range), 245.03 (126.23–317.43) pg/mL] to the N-DM group [170.05 (89.01–244.70) pg/mL] and, finally, to the DM group [142.25 (55.55–187.58) pg/mL] (p for trend < 0.05). Among subjects in the DM group, there was a positive trend in the serum FGF19 concentration; plasma insulin levels at 60 min, 120 min (INS60, INS120, respectively); and area under the insulin curve (AUC(ins)) at two points (r = 0.214, p = 0.025; r = 0.189, p = 0.048; r = 0.188, p = 0.049). However, the differences were no longer observed among the N-DM subjects. Simultaneously, the ISSI-2 was closely related to the serum FGF19 levels (r = 0.297, p = 0.002) among DM subjects. Furthermore, after adjusting for age, sex, duration, therapy and other clinical factors via multiple logistic regression analysis, ISSI-2 was a key independent factor in the levels of FGF19 (β = 0.281, t = 2.557, p = 0.013). CONCLUSIONS: The serum FGF19 level has a close relation with endogenous beta cell function among DM subjects, as assessed by the ISSI-2. As ISSI-2 is higher in N-DM group, FGF19 may be a main protector in dysfunction of beta cell. BioMed Central 2019-09-24 /pmc/articles/PMC6760053/ /pubmed/31572498 http://dx.doi.org/10.1186/s13098-019-0475-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tang, Meng-jie
Su, Jian‑bin
Xu, Tian-li
Wang, Xue‑qin
Zhang, Dong-mei
Wang, Xiao-hua
Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients
title Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients
title_full Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients
title_fullStr Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients
title_full_unstemmed Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients
title_short Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients
title_sort serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760053/
https://www.ncbi.nlm.nih.gov/pubmed/31572498
http://dx.doi.org/10.1186/s13098-019-0475-1
work_keys_str_mv AT tangmengjie serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients
AT sujianbin serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients
AT xutianli serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients
AT wangxueqin serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients
AT zhangdongmei serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients
AT wangxiaohua serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients